This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor:
—In the April 24, 1954, issue of The Journal there is a two page ad for ethyl biscoumacetate (Tromexan ethyl acetate) by the Geigy Chemical Corporation in which they quote from a paper of mine (Med. Times81:605, 1953). In this advertisement there is a quotation from my paper: "... rapid absorption, action and excretion as well as shorter action and reduced cumulative effect, characteristics which mean greater safety." In the article I made the following statement: "Compared with Dicumarol, Tromexan has the advantage of more rapid absorption, action and excretion, as well as shorter action and reduced cumulative effect, characteristics which mean greater safety. Reduced cumulative effect, however, does not indicate complete freedom from the danger of cumulative action inherent in the use of this type of anticoagulant." As can be seen, in the advertisement the Geigy Corporation deleted the words "Compared with Dicumarol" and deleted
Blaustein A. ADVERTISING. JAMA. 1954;155(11):1006. doi:10.1001/jama.1954.03690290056023